Literature DB >> 28555362

The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware.

Maricruz Vega1, Manisha Verma2, David Beswick3, Stephanie Bey3, Jared Hossack4, Nathan Merriman3, Ashish Shah5, Victor Navarro2.   

Abstract

BACKGROUND AND AIM: The population-based incidence rate of drug-induced liver injury (DILI) in the USA is not known. The Drug-Induced Liver Injury Network (DILIN) accrues cases of hepatotoxicity due to medications and herbal and dietary supplements (HDS) from limited geographical areas. The current analysis was an ancillary study of DILIN aimed at determining the annual incidence of DILI in the USA on a population basis, through surveillance in the state of Delaware.
METHODS: At the outset of the study, there were 41 gastroenterologists in the state of Delaware and all agreed to participate in surveillance for DILI, which comprised active reporting of suspected cases to the DILIN. The gastroenterologists underwent training in the diagnosis of DILI and were provided with DILIN inclusion criteria. Only cases that met the DILIN laboratory inclusion criteria in 2014 were included in the incidence calculation, and these patients were invited to participate in the DILIN Prospective Study. The number of suspected cases that met inclusion criteria served as the numerator and the 2014 Delaware adult population as the denominator.
RESULTS: During 2014, 23 patients were identified by the surveillance network, 20 of whom met DILIN laboratory inclusion criteria, leading to an incidence of 2.7 cases of DILI per 100,000 adult residents [95% confidence interval (CI) 1.5-3.9 per 100,000]. Fourteen subjects agreed to participate in the DILIN; six declined. Among enrolled cases, the mean age was 51 years, 57% were women, and 71% were white. Eight cases were attributed to antibiotics (36%) and other drugs (21%) and six to HDS (43%). The pattern of injury was hepatocellular in all HDS cases, but only 50% of conventional drug cases (p = 0.05), which more commonly presented with eosinophilia (p = 0.47) and higher alkaline phosphatase levels (p = 0.05). Half of patients were jaundiced, none developed liver failure, and all recovered without the need for transplantation.
CONCLUSION: Prospective, gastroenterologist-based surveillance for suspected DILI in Delaware yielded an incidence of 2.7 cases per 100,000 adults in 2014; this is the first prospective estimate of DILI for the USA. Because surveillance was limited to subspecialists, the actual incidence of DILI is likely to be higher. These findings provide a benchmark statistic for the epidemiology of DILI in the United States, to be refined with expansion of the surveillance period.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28555362      PMCID: PMC5699929          DOI: 10.1007/s40264-017-0547-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  11 in total

1.  Under-reporting of adverse drug reactions in general practice.

Authors:  Y Moride; F Haramburu; A A Requejo; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

2.  The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].

Authors:  Mark V Galan; Jeffrey A Potts; Ann L Silverman; Stuart C Gordon
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

3.  Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic.

Authors:  M B De Valle; V Av Klinteberg; N Alem; R Olsson; E Björnsson
Journal:  Aliment Pharmacol Ther       Date:  2006-10-15       Impact factor: 8.171

4.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

Authors:  Einar S Björnsson; Ottar M Bergmann; Helgi K Björnsson; Runar B Kvaran; Sigurdur Olafsson
Journal:  Gastroenterology       Date:  2013-02-16       Impact factor: 22.682

5.  Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.

Authors:  Victor J Navarro; Huiman Barnhart; Herbert L Bonkovsky; Timothy Davern; Robert J Fontana; Lafaine Grant; K Rajender Reddy; Leonard B Seeff; Jose Serrano; Averell H Sherker; Andrew Stolz; Jayant Talwalkar; Maricruz Vega; Raj Vuppalanchi
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

6.  Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system.

Authors:  David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re
Journal:  Gastroenterology       Date:  2015-02-28       Impact factor: 22.682

7.  Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?

Authors:  Raj Vuppalanchi; Suthat Liangpunsakul; Naga Chalasani
Journal:  Am J Gastroenterol       Date:  2007-03       Impact factor: 10.864

8.  Incidence of drug-induced hepatic injuries: a French population-based study.

Authors:  Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

9.  Acute and clinically relevant drug-induced liver injury: a population based case-control study.

Authors:  Francisco J de Abajo; Dolores Montero; Mariano Madurga; Luis A García Rodríguez
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

10.  Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Authors:  Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more
  21 in total

1.  Acetaminophen-Induced Liver Injury Alters Expression and Activities of Cytochrome P450 Enzymes in an Age-Dependent Manner in Mouse Liver.

Authors:  Yifan Bao; Pei Wang; Xueyan Shao; Junjie Zhu; Jingcheng Xiao; Jian Shi; Lirong Zhang; Hao-Jie Zhu; Xiaochao Ma; José E Manautou; Xiao-Bo Zhong
Journal:  Drug Metab Dispos       Date:  2020-02-24       Impact factor: 3.922

2.  Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice.

Authors:  Dahea You; Lascelles E Lyn-Cook; Daniel M Gatti; Natalie Bell; Philip R Mayeux; Laura P James; William B Mattes; Gary J Larson; Alison H Harrill
Journal:  Toxicol Sci       Date:  2020-06-01       Impact factor: 4.849

Review 3.  Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Expert Rev Mol Diagn       Date:  2018-08-13       Impact factor: 5.225

Review 4.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

5.  Liver Injury Associated With Drugs and Complementary and Alternative Medicines in India.

Authors:  Einar S Björnsson
Journal:  J Clin Exp Hepatol       Date:  2021-04-27

6.  Liver Injury Following Tinospora Cordifolia Consumption: Drug-Induced AIH, or de novo AIH?

Authors:  Einar S Björnsson; Victor J Navarro; Naga Chalasani
Journal:  J Clin Exp Hepatol       Date:  2021-11-29

Review 7.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

8.  Effects of medium- and long-chain fatty acids on acetaminophen- or rifampicin-induced hepatocellular injury.

Authors:  Jun Yang; Ting Peng; Jiyong Huang; Guohua Zhang; Jiaheng Xia; Maomao Ma; Danwen Deng; Deming Gong; Zheling Zeng
Journal:  Food Sci Nutr       Date:  2020-05-19       Impact factor: 2.863

9.  HLA-B*35:01 and Green Tea-Induced Liver Injury.

Authors:  Jay H Hoofnagle; Herbert L Bonkovsky; Elizabeth J Phillips; Yi-Ju Li; Jawad Ahmad; Huiman Barnhart; Francisco Durazo; Robert J Fontana; Jiezhun Gu; Ikhlas Khan; David E Kleiner; Christopher Koh; Don C Rockey; Leonard B Seeff; Jose Serrano; Andrew Stolz; Hans L Tillmann; Raj Vuppalanchi; Victor J Navarro
Journal:  Hepatology       Date:  2021-05-17       Impact factor: 17.425

10.  Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system.

Authors:  Mohamed Kadry Taher; Abdallah Alami; Christopher A Gravel; Derek Tsui; Lise M Bjerre; Franco Momoli; Donald R Mattison; Daniel Krewski
Journal:  JGH Open       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.